Gyre Therapeutics, Inc. Deferred Tax Assets, Operating Loss Carryforwards
Gyre Therapeutics, Inc. (GYRE) had Deferred Tax Assets, Operating Loss Carryforwards of $42.24 million as of 2025-12-31, per its 10-K filed 2026-03-13.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-13
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $42.24M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $41.71M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $40.67M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $40.77M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $42.24M 10-K · filed 2026-03-13 | |
| 2024-12-31 | $41.71M 10-K · filed 2026-03-13 | |
| 2023-12-31 | $40.67M 10-K · filed 2025-03-17 | |
| 2022-12-31 | $40.77M 10-K · filed 2023-03-30 | |
| 2021-12-31 | $47.54M 10-K · filed 2023-03-30 | |
| 2020-12-31 | $29.50M 10-K · filed 2022-03-31 | |
| 2019-12-31 | $34.39M 10-K · filed 2021-03-04 | |
| 2018-12-31 | $23.56M 10-K · filed 2020-02-20 | |
| 2017-12-31 | $11.52M 10-K · filed 2019-03-08 | |
| 2016-12-31 | $25.94M 10-K · filed 2018-03-19 | |
| 2015-12-31 | $17.65M 10-K · filed 2017-03-08 | |
| 2014-12-31 | $44.08M 10-K · filed 2016-03-09 | $94.76M 10-K · filed 2015-03-16 |
| 2013-12-31 | $42.83M 8-K/A · filed 2015-10-23 | $81.18M 10-K · filed 2014-03-14 |
| 2012-12-31 | $65.94M 10-K · filed 2014-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |